hypothyroidism
HYPOTHYROIDISM
Hypothyroidism is a common endocrine disorder where in the thyroid does not make enough thyroid hormone.
Subclinical/mild hypothyroidism refers to the state of slightly increased serum TSH with normal serum FT4 in patients who are usually asymptomatic.
Most common cause of primary hypothyroidism is autoimmune thyroiditis or Hashimoto's disease.
Levothyroxine is the first-line agent for treatment of hypothyroidism.

Hypothyroidism Treatment

Pharmacotherapy

Levothyroxine

  • 1st-line agent for treatment of hypothyroidism
  • May be used to manage myxedema coma
  • Safe for use in pregnancy
  • Actions:
    • Used as a replacement therapy in hypothyroidism to substitute thyroid hormone
    • Long half-life (T½), slow onset, regular bioconversion which is appropriately regulated by the tissues to the biologically active compound T3
  • Effects: Safe and predictable effects
    • Requires several weeks to achieve peak therapeutic effects with regular oral dosing
  • Due to different bioavailability of the various preparations of Levothyroxine, patients are encouraged to use the same brand of Levothyroxine
    • If a change in brand is needed, the patient’s serum TSH should be retested every 6 weeks and dosage of Levothyroxine be re-titrated

Liothyronine

  • Actions:
    • Short T½, rapid onset
    • Biologically active compound (no conversion is necessary)
    • Used as a replacement therapy in hypothyroidism to substitute thyroid hormone
  • Generally not recommended for routine treatment of hypothyroidism due to its rapid onset and turnover which requires more frequent administration and increases the risk of hyperthyroidism
  • Useful in management of myxedema coma (when its rapid onset and short duration of action are required)
  • Effects: Require 3 days to achieve peak therapeutic effects
Note: Desiccated thyroid hormones (with variable proportion of T3 and T4), combinations of thyroid hormones and T3 alone are generally not recommended for treatment of hypothyroidism.
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Pearl Toh, 6 days ago
Inhaled corticosteroid (ICS) should be the mainstay of long-term asthma management — such is the key message of the latest Singapore ACE* Clinical Guidance (ACG) for asthma, released in October 2020.
Elvira Manzano, 17 Nov 2020
Invasive fungal infections, particularly those caused by Candida species, are common in hospitalized, immunocompromised, or critically ill patients and are associated with considerable morbidity and mortality.